Inflarx looks to its lead asset in a rare skin disease, while smoking cessation success could trigger partnering talks for Achieve Life Sciences.
December will be a big month for Achillion's complement inhibitor and Aquestive's ALS hopes.
Loosening of clinical requirements has encouraged more projects into the IgA nephropathy pipeline, with a steroid–based approach from Sweden’s Calliditas looking…
Deals were a major driver of mid-cap share movement in the first quarter, but pipeline progress and misfires played their parts too.
The drugs of 2014 that went supernova and those that failed to make orbit.